ORAI1 and COVID-19: A number of pharmacological inhibitors have now reached clinical trials for severe plaque psoriasis, acute pancreatitis, asthma and coronavirus disease 2019 (COVID-19)-associated severe pneumonia (Stauderman, 2018; Miller et al., 2020), which highlights the therapeutic potential of the ORAI1 channel inhibitors and the tolerability of the ORAI1 inhibitors in patients.